Epigeneres Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.30 M
as on 16-11-2024
- Paid Up Capital ₹ 0.26 M
as on 16-11-2024
- Company Age 12 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 80.56%
(FY 2023)
- Profit -439.54%
(FY 2023)
- Ebitda -373.49%
(FY 2023)
- Net Worth -17.14%
(FY 2023)
- Total Assets -10.80%
(FY 2023)
About Epigeneres Biotech
The Corporate was formerly known as Trivinay Bio-Tech Private Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.30 M and a paid-up capital of Rs 0.26 M, as per Ministry of Corporate Affairs (MCA) records.
Krishnan Challam, Sanjay Pravinchandra, Bhavna Roy, and Four other members serve as directors at the Company.
- CIN/LLPIN
U29253MH2012PTC230235
- Company No.
230235
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Apr 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Epigeneres Biotech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anish Tripathi  | Managing Director | 05-May-2019 | Current |
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Krishnan Challam | Director | 29-Feb-2016 | Current |
| Ashish Tripathi | Director | 29-Feb-2016 | Current |
| Sanjay Pravinchandra | Director | 30-Sep-2023 | Current |
| Bhavna Roy | Director | 10-Jan-2022 | Current |
| Amish Tripathi | Director | 21-Jun-2021 | Current |
Moez Daya  | Nominee Director | 10-Jan-2022 | Current |
Financial Performance and Corporate Structure Insights of Epigeneres Biotech.
Epigeneres Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 80.56% increase. The company also saw a substantial fall in profitability, with a 439.54% decrease in profit. The company's net worth observed a substantial decline by a decrease of 17.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Epigeneres Biotech?
In 2023, Epigeneres Biotech had a promoter holding of 73.10% and a public holding of 26.90%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Epigeneres Biotech?
Epigeneres Biotech has a workforce of 76 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Epigeneres Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Epigeneres Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
